Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial

Abstract

Methotrexate conferred a significant advantage in participants with moderately active lupus by lowering daily prednisone dose and slightly decreasing lupus disease activity. As a therapeutic option in moderate SLE, methotrexate can be considered to be steroid sparing.